Progress in the Management of Gliomas Conference

Event Notes:

The programme will highlight current clinical trial options for recurrent glioblastoma, oncological management options for recurrent grade 3 IDH-mutant astrocytoma, and the emerging experience with vorasidenib in the treatment of low-grade gliomas, alongside updates from the INDIGO study.

The conference will also cover relevant topics such as seizure management, psychological support, advanced imaging techniques for gliomas, updates on neurosurgery, offering attendees a comprehensive view of progress across the spectrum of glioma management.

The conference is open to all healthcare professionals involved in the challenges of caring for patients with Low-Grade Gliomas, including and in particular, clinicians, senior nurses and therapy radiographers.

CPD accreditation applied for from The Royal College of Physicians